1. Home
  2. DRI vs INCY Comparison

DRI vs INCY Comparison

Compare DRI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Darden Restaurants Inc.

DRI

Darden Restaurants Inc.

SELL

Current Price

$231.56

Market Cap

22.4B

ML Signal

SELL

Logo Incyte Corp.

INCY

Incyte Corp.

SELL

Current Price

$119.83

Market Cap

24.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DRI
INCY
Founded
1968
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.4B
24.5B
IPO Year
2000
1994

Fundamental Metrics

Financial Performance
Metric
DRI
INCY
Price
$231.56
$119.83
Analyst Decision
Buy
Buy
Analyst Count
28
28
Target Price
★ $233.44
$132.25
AVG Volume (30 Days)
817.5K
★ 1.6M
Earning Date
12-17-2026
10-29-2026
Dividend Yield
★ 2.81%
N/A
EPS Growth
17.16
★ 4173.33
EPS
★ 2.04
0.50
Revenue
★ $13,210,900,000.00
$3,394,635,000.00
Revenue This Year
$3.73
$17.74
Revenue Next Year
$6.07
$4.35
P/E Ratio
★ $113.23
$240.54
Revenue Growth
9.39
★ 13.67
52 Week Low
$169.00
$89.25
52 Week High
$233.98
$132.60

Technical Indicators

Market Signals
Indicator
DRI
INCY
Relative Strength Index (RSI) 65.00 51.36
Support Level $191.40 $115.38
Resistance Level $231.87 $130.53
Average True Range (ATR) 5.37 3.97
MACD 0.33 0.24
Stochastic Oscillator 81.92 66.41

Price Performance

Historical Comparison
DRI
INCY

About DRI Darden Restaurants Inc.

Darden Restaurants is the largest global full-service dining operator, with over $13 billion in system sales across 2,202 company-owned stores at the end of fiscal 2026, spanning the US and Canada. The firm operates 10 banners in four segments, including Olive Garden (42% of sales), LongHorn Steakhouse (26%), and fine dining (21%), which includes The Capital Grille, Ruth's Chris, and Eddie V's. The other 11% of sales comes from smaller concepts such as Yard House and Cheddar's. Darden primarily generates revenue through sales of food and beverage items at its company-owned restaurants. It also earns royalties on sales from 167 franchised locations in US and international markets, which sit within the other segment but are immaterial to consolidated results.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Share on Social Networks: